2. Search Result
Search Result
Results for "

CHF

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

2

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-U00302
    CHF5407

    		mAChR Inflammation/Immunology
    CHF5407 is a selective, long-acting and competitive muscarinic M3 receptor antagonist. CHF5407 shows subnanomolar affinities for human muscarinic M1 (hM1), M2 (hM2) and M3 (hM3) receptors. CHF5407 shows a prolonged antibronchospastic activity .
    CHF5407
  • HY-19929
    Tanimilast

    CHF-6001

    		 Phosphodiesterase (PDE) NF-κB Interleukin Related CXCR CCR TNF Receptor Inflammation/Immunology
    Tanimilast (CHF-6001) is an orally active and selective phosphodiesterase 4 inhibitor (IC50=0.026 nM) with robust anti-inflammatory activity and suitable for topical pulmonary administration. Tanimilast increases cellular cAMP levels, and inhibits NF-κB signaling pathway. Tanimilast is used for the research of obstructive lung diseases .
    Tanimilast
  • HY-151198
    CHF-6366

    		mAChR Adrenergic Receptor Calcium Channel Inflammation/Immunology Endocrinology
    CHF-6366 is a potent M3 muscarinic antagonist and β2-adrenergic receptors agonist with pKi values of 10.4 and 11.4, respectively. CHF-6366 is also a weak calcium channel inhibitor (IC50~50 μM). CHF-6366 inhibits bronchoconstriction in guinea pigs. CHF-6366 can be used to research chronic obstructive pulmonary disease (COPD) .
    CHF-6366
  • HY-163702
    CHF-6550

    		Adrenergic Receptor mAChR Inflammation/Immunology
    CHF-6550 is an antagonist for muscarinic M3 receptor and an agonist for β2 adrenoceptor (MABA), with pKi of 9.3 and 10.6, respectively. CHF-6550 exhibits good hepatocyte clearance in rat models and good pharmacokinetic characteristics in guinea pigs .
    CHF-6550
  • HY-162878
    CHF-6523

    		PI3K Inflammation/Immunology
    CHF-6523 is an orally active PI3Kδ inhibitor that can be used in research related to chronic obstructive pulmonary disease (COPD) .
    CHF-6523
  • HY-101440A
    Indantadol hydrochloride

    CHF-3381

    		 iGluR Neurological Disease
    Indantadol (CHF-3381) hydrochloride is a novel putative NMDA antagonist. Indantadol blocks the NMDA receptor in a dose-dependent and prevents cell damage .
    Indantadol hydrochloride
  • HY-123228
    CHF5022

    		Amyloid-β Neurological Disease
    CHF5022 is an inhibitor of Aβ42 secretion (IC50=92 μM). CHF5022 retains a modest activity on Aβ40 at non-cytotoxic concentrations (−22.2±4.8% at 100 μM) .
    CHF5022
  • HY-107045
    CHF 4227 free base

    		Estrogen Receptor/ERR Endocrinology
    CHF 4227 free base is an orally active and selective estrogen receptor modulator (SERM) with high affinity to the human estrogen receptor-α and -β (Ki values of 0.017 nM and 0.099 nM, respectively) .
    CHF 4227 free base
  • HY-106973A
    Nolomirole hydrochloride

    CHF 1035

    		 Dopamine Receptor Adrenergic Receptor Cardiovascular Disease
    Nolomirole (CHF 1035) hydrochloride is an orally active and selective DA2 dopaminergic receptor/α2-adrenoceptor agonist. Nolomirole attenuates the heart failure signs in the Monocrotaline (HY-N0750)-induced congestive heart failure model. Nolomirole increases cardiac output .
    Nolomirole hydrochloride
  • HY-106973
    Nolomirole

    CHF 1035 free base

    		 Dopamine Receptor Adrenergic Receptor Cardiovascular Disease
    Nolomirole (CHF 1035) is an orally active and selective DA2 dopaminergic receptor/α2-adrenoceptor agonist. Nolomirole attenuates the heart failure signs in the Monocrotaline (HY-N0750)-induced congestive heart failure model. Nolomirole increases cardiac output .
    Nolomirole
  • HY-14399
    Itanapraced
    1 Publications Verification

    CHF5074; CSP-1103

    		 γ-secretase Apoptosis Neurological Disease
    Itanapraced (CHF5074) is an orally active γ-secretase modulator and a non-steroidal anti-inflammatory derivative. Itanapraced reduces Aβ42 and Aβ40 secretion with IC50 values of 3.6 and 18.4 μM, respectively. Itanapraced inhibits cell apoptosis of hippocampal neurons induced by oxygen and glucose deprivation (OGD). Itanapraced can be used for the research of Alzheimer's disease .
    Itanapraced
  • HY-19929A
    (R)-Tanimilast

    (R)-CHF-6001

    		 Phosphodiesterase (PDE) Inflammation/Immunology
    (R)-Tanimilast is a isomeride of Tanimilast (HY-19929). Tanimilast (CHF-6001) is a novel highly potent and selective phosphodiesterase 4 inhibitor (IC50=0.026 nM) .
    (R)-Tanimilast
  • HY-B0592
    Trandolapril

    RU44570

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    Trandolapril
  • HY-B0592A
    Trandolapril hydrochloride

    RU44570 hydrochloride

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril (RU44570) hydrochloride is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolapril hydrochlorideat. Trandolapril hydrochloride is an orally active angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    Trandolapril hydrochloride
  • HY-B0592R
    Trandolapril (Standard)

    RU44570 (Standard)

    		 Reference Standards Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril (Standard) is the analytical standard of Trandolapril. This product is intended for research and analytical applications. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    Trandolapril (Standard)
  • HY-18207
    Fasidotril

    Alatriopril

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Fasidotril is a dual inhibitor of neprilysin and angiotensin-converting enzyme (ACE) for the potential research of hypertension and congestive heart failure (CHF).
    Fasidotril
  • HY-B0592S
    Trandolapril-d5

    RU44570 d5

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril-d5 is a deuterium labeled Trandolapril (RU44570). Trandolapril is an orally active angiotensin converting enzyme (ACE) inhibitor for hypertension and congestive heart failure (CHF) .
    Trandolapril-d5
  • HY-118472R
    Benazeprilat (Standard)

    CGS 14831 (Standard)

    		 Drug Metabolite Reference Standards Endogenous Metabolite Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Benazeprilat (Standard) is the analytical standard of Benazeprilat. This product is intended for research and analytical applications. Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage .
    Benazeprilat (Standard)
  • HY-118472
    Benazeprilat

    CGS 14831

    		 Drug Metabolite Endogenous Metabolite Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage .
    Benazeprilat
  • HY-120577
    BA 41899

    		Calcium Channel Cardiovascular Disease
    BA 41899 is a purely calcium-sensitizing agent. BA 41899 is completely devoid of phosphodiesterase (PDE) III inhibitory activity or any other known inotropic mechanism. BA 41899 can be used for the research of cardiovascular diseases, such as congestive heart failure (CHF) .
    BA 41899
  • HY-B0205
    Candesartan
    5 Publications Verification

    CV 11974

    		 Angiotensin Receptor PPAR Cardiovascular Disease Endocrinology Cancer
    Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .
    Candesartan
  • HY-W744298
    Trandolapril-d3

    		Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril-d3 is the deuterium labeled Trandolapril (HY-B0592). Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    Trandolapril-d3
  • HY-B0205R
    Candesartan (Standard)

    CV 11974 (Standard)

    		 Reference Standards Angiotensin Receptor PPAR Cardiovascular Disease Endocrinology Cancer
    Candesartan (Standard) is the analytical standard of Candesartan. This product is intended for research and analytical applications. Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .
    Candesartan (Standard)
  • HY-B0592S2
    rac-Trandolapril-d5

    rac-RU44570-d5

    		 Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    rac-Trandolapril-d5 (rac-RU44570-d5) is deuterium labeled Trandolapril. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    rac-Trandolapril-d5
  • HY-15718B
    Istaroxime oxalate

    PST2744 oxalate

    		 Na+/K+ ATPase Cardiovascular Disease
    Istaroxime oxalate (PST2744 oxalate) is the oxalate form of Istaroxime (HY-15718). Istaroxime oxalate is is an inotropic agent, that inhibits Na +/K +-ATPase with an IC50 of 0.11 μM. Istaroxime oxalate increases force of contraction in guinea pig atria and twitch amplitude in isolated guinea pig myocytes without causing lethal arrhythmias .
    Istaroxime oxalate
  • HY-B0205S
    Candesartan-d4

    CV-11974-d4

    		 Angiotensin Receptor Others
    Candesartan-d4 (CV-11974-d4) is the deuterium labeled Candesartan (HY-B0205). Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI).
    Candesartan-d4
  • HY-14399R
    Itanapraced (Standard)

    		γ-secretase Apoptosis Neurological Disease
    Itanapraced (Standard) is the analytical standard of Itanapraced. This product is intended for research and analytical applications. Itanapraced (CHF5074) is an orally active γ-secretase modulator and a non-steroidal anti-inflammatory derivative. Itanapraced reduces Aβ42 and Aβ40 secretion with IC50 values of 3.6 and 18.4 μM, respectively. Itanapraced inhibits cell apoptosis of hippocampal neurons induced by oxygen and glucose deprivation (OGD). Itanapraced can be used for the research of Alzheimer's disease .
    Itanapraced (Standard)
  • HY-B0205G
    Candesartan

    CV 11974

    		 Angiotensin Receptor PPAR Cardiovascular Disease Endocrinology Cancer
    Candesartan (GMP) (CV 11974 (GMP)) is Candesartan (HY-B0205) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .
    Candesartan
  • HY-106045
    Imazodan

    CI 914 free base

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    Imazodan is a selective inhibitor for phosphodiesterase III (PDE III), which increases myocardial contractility by blocking the cAMP degradation, and improves the contractile function of heart. Imazodan serves also as a peripheral vasodilator .
    Imazodan
  • HY-106045A
    Imazodan hydrochloride

    CI 914

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    Imazodan hydrochloride is the hydrochloride form of Imazodan (HY-106045). Imazodan hydrochloride is a selective inhibitor for phosphodiesterase III (PDE III), which increases myocardial contractility by blocking the cAMP degradation, and improves the contractile function of heart. Imazodan hydrochloride serves also as a peripheral vasodilator .
    Imazodan hydrochloride
  • HY-106994
    Nebentan

    YM598 free base

    		 Endothelin Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Nebentan (YM598 free base) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan inhibits [ 125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively . YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo .
    Nebentan
  • HY-123348
    Sampatrilat

    UK-81252

    		 Angiotensin-converting Enzyme (ACE) Neprilysin Cardiovascular Disease Inflammation/Immunology
    Sampatrilat (UK-81252) is a potent and orally active vasopeptidase inhibitor of ACE and neutral endopeptidase (NEP). Sampatrilat inhibits C-domain ACE (Ki=13.8 nM) 12.4-fold more potent than that for the N-domain (Ki=171.9 nM). Sampatrilat (UK-81252) can be used for the study of chronic heart failure and blood pressure regulation .
    Sampatrilat
  • HY-106994A
    Nebentan potassium

    YM598

    		 Endothelin Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Nebentan potassium (YM598) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan potassium inhibits [ 125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively . YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo .
    Nebentan potassium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: